隶属于 Shire Plc
相关临床试验
7
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1989
进行中（未招募）
6
85.7%
已完成
1
14.3%
暂无批准数据
- KALA BIO has appointed Todd Bazemore as permanent President and CEO, transitioning from his interim role since February 2025. - The company is approaching a critical Phase 2b CHASE trial readout for KPI-012 in persistent corneal epithelial defect, a rare orphan disease with no FDA-approved treatments. - Bazemore brings over 30 years of biopharmaceutical experience and will lead KALA's potential transition from clinical-stage to commercial operations. - KPI-012 utilizes KALA's proprietary mesenchymal stem cell secretome platform and has received Orphan Drug and Fast Track designations from the FDA.
- Enara Bio has appointed Stacey Davis as Chief Business Officer and Chief Financial Officer, bringing over 25 years of biotech experience to strengthen the company's business development and capital strategy. - Clive Wood, Ph.D., former Global Head of Discovery Research at Boehringer Ingelheim and discoverer of the PD-1: PD-L1/PD-L2 pathway, joins Enara's board as Non-executive Director. - The leadership appointments come as Enara prepares to transition its lead Dark Antigen-targeted T-cell engager assets toward clinical development. - The company's EDAPT platform enables discovery of cancer-specific antigens from previously uncharted genomic 'dark matter' for developing TCR-based immunotherapies against solid tumors.
